Anticoagulation in COVID-19: Effect of Enoxaparin, Heparin, and Apixaban on Mortality.

Henny H BillettMorayma Reyes-GilJames M SzymanskiKenji IkemuraLindsay R StahlYungtai LoShafia RahmanJesus D Gonzalez-LugoMargarita KushnirMohammad BarouqaLadan GolestanehEran Bellin

Published in: Thrombosis and haemostasis (2020)

We conclude that COVID-19+ patients with moderate or severe illness benefit from anticoagulation and that apixaban has similar efficacy to enoxaparin in decreasing mortality in this disease.

Keyphrases

venous thromboembolism
coronavirus disease
sars cov
cardiovascular events
atrial fibrillation
risk factors
respiratory syndrome coronavirus
early onset
type diabetes
growth factor